The official website of the National Health Insurance Bureau issued a notice on March 21st that the provincial health insurance departments should, in accordance with the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth) and the New Coronavirus pneumonia prevention and control program (trial version ninth), take into consideration the needs of epidemic prevention and control and the payment ability of the medical insurance fund in the region, and promptly adjust and optimize the relevant policies of medical insurance according to the principles of scientific precision, positive and prudent and controllable risk.
The notice specifically pointed out that each provincial medical security department should temporarily include covid-19 virus antigen detection reagent and corresponding detection items into the catalogue of basic medical insurance medical service items in the province according to procedures. The relevant expenses incurred by the insured in the designated grass-roots medical institutions shall be paid according to the current provisions of the overall planning area. The expenses of purchasing testing reagents in the designated retail pharmacies can be paid by personal accounts. Local pharmaceutical centralized procurement institutions should do a good job in the network connection of covid-19 virus antigen detection reagents, actively promote the network connection procurement, and rely on the national unified medical insurance information platform for information sharing.
At the same time, covid-19 treatment drugs included in the payment scope of medical insurance shall be adjusted in time. The newly added nimatovir tablets / ritonavir tablets in the diagnosis and treatment plan (trial version 9) shall be purchased by the medical institution according to the price agreed between the enterprise and relevant departments, and the medical insurance department shall pay according to the regulations.
In addition, medical security departments at all levels should support the normal operation of medical institutions in areas with serious epidemic, and if necessary, prepay part of covid-19 treatment funds according to procedures. We will solidly ensure the cost of covid-19 virus vaccine and vaccination, earnestly implement the price policy of nucleic acid and antigen testing projects, implement the settlement and reimbursement policies such as "long-term prescription" and Internet diagnosis and treatment, ensure the implementation of various epidemic prevention and control medical security policies, reduce the number of insured patients seeking medical treatment and dispensing in medical institutions, and effectively reduce the safety risk of epidemic transmission.
